Company news

Nurix Therapeutics, Inc. news in 2026

Nurix Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

October 12, 2026

Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia

October 5, 2026

Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences

October 5, 2026

Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer

September 29, 2026

Nurix Therapeutics to Participate in Upcoming September Investor Conferences

September 1, 2026

Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer

August 20, 2026

Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader

August 4, 2026

Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

August 4, 2026

Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

July 21, 2026

Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

July 9, 2026

Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy

June 11, 2026

Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

June 8, 2026

Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress

May 12, 2026

Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026

April 22, 2026

Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

April 7, 2026

Nurix Therapeutics to Participate in Upcoming Investor Conference

April 7, 2026

Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting

March 22, 2026

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update

January 28, 2026

Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases

January 11, 2026

Nurix Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

January 4, 2026

Decks in 2026